Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T Therapy in Relapsed/Refractory Multiple Myeloma
NCT03473496Terminated
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Mar 2018
- Primary completion
- Jan 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of anti-BCMA CAR-T and anti-CD38 chimeric antigen receptor T-cell in multiple myeloma (MM), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Adverse events that Are related to treatment at 2 years. Started Mar 2018; status: terminated.
02
Drugs
anti-BCMA CAR-Tanti-CD38 chimeric antigen receptor T-cell
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03473496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03473496.